Literature DB >> 18320219

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.

Véronique Mersseman1, Verena Böhm, Rafaela Holtappels, Petra Deegen, Uwe Wolfrum, Bodo Plachter, Sabine Reyda.   

Abstract

Development of a vaccine against human cytomegalovirus (HCMV) infection has been identified as a high priority goal in biomedical research, yet no vaccine has been licensed until now. Recombinant subviral dense bodies (recDB) are a promising basis for the establishment of such a vaccine. In this article, strategies for the generation of recDB, based on recombination-mediated genetic engineering of the 230 kb HCMV DNA genome in E. coli are outlined. Analysis of viral mutants that were constructed in this process provided the proof-of-principle that heterologous antigens can be packaged into recDB and that these particles prime CD8 T cell responses against the recombinant antigen upon their application to HLA-A2 transgenic mice.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18320219     DOI： 10.1007/s00430-008-0085-2

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  49 in total

1.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.

Authors:  Simon F Lacey; Corinna La Rosa; Wendy Zhou; Madeva C Sharma; Joy Martinez; Aparna Krishnan; Ghislaine Gallez-Hawkins; Lia Thao; Jeff Longmate; Ricardo Spielberger; Stephen J Forman; Ajit Limaye; John A Zaia; Don J Diamond
Journal:  J Infect Dis       Date:  2006-10-11       Impact factor: 5.226

3.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Human bone marrow fibroblasts infected by cytomegalovirus: ultrastructural observations.

Authors:  J Gilloteaux; M R Nassiri
Journal:  J Submicrosc Cytol Pathol       Date:  2000-01

5.  Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus.

Authors:  Nadine Frankenberg; Sandra Pepperl-Klindworth; Ralf G Meyer; Bodo Plachter
Journal:  Virology       Date:  2002-04-10       Impact factor: 3.616

6.  CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation.

Authors:  Christian O Simon; Rafaela Holtappels; Hanna-Mari Tervo; Verena Böhm; Torsten Däubner; Silke A Oehrlein-Karpi; Birgit Kühnapfel; Angélique Renzaho; Dennis Strand; Jürgen Podlech; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

7.  Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants.

Authors:  E M Borst; G Hahn; U H Koszinowski; M Messerle
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

8.  Protein delivery by subviral particles of human cytomegalovirus.

Authors:  S Pepperl-Klindworth; N Frankenberg; S Riegler; B Plachter
Journal:  Gene Ther       Date:  2003-02       Impact factor: 5.250

9.  Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response.

Authors:  J Beninga; B Kropff; M Mach
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

10.  Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort.

Authors:  Marianne A B van der Sande; Steve Kaye; David J C Miles; Pauline Waight; David J Jeffries; Olubukola O Ojuola; Melba Palmero; Margaret Pinder; Jamila Ismaili; Katie L Flanagan; Akum A Aveika; Akram Zaman; Sarah Rowland-Jones; Samuel J McConkey; Hilton C Whittle; Arnaud Marchant
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240
View more
  7 in total

Review 1.  Oncomodulation by human cytomegalovirus: evidence becomes stronger.

Authors:  Martin Michaelis; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

2.  Cytomegalovirus UL103 controls virion and dense body egress.

Authors:  Jenny Ahlqvist; Edward Mocarski
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

Review 3.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

4.  Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.

Authors:  Caroline Lehmann; Jessica Julia Falk; Nicole Büscher; Inessa Penner; Christine Zimmermann; Patricia Gogesch; Christian Sinzger; Bodo Plachter
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

Review 5.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

6.  The Abundant Tegument Protein pUL25 of Human Cytomegalovirus Prevents Proteasomal Degradation of pUL26 and Supports Its Suppression of ISGylation.

Authors:  Christine Zimmermann; Nicole Büscher; Steffi Krauter; Nadine Krämer; Uwe Wolfrum; Elisabeth Sehn; Stefan Tenzer; Bodo Plachter
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

Review 7.  Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development.

Authors:  Giuseppe Gerna; Daniele Lilleri
Journal:  Vaccines (Basel)       Date:  2020-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.